BKGI 株価分析 — Bangkok Genomics Innovation Public Company Limited (Healthcare >> Diagnostics & Research)

Description: Bangkok Genomics Innovation Public Company Limited provides medical analysis services in Thailand. The company offers screening for fetal chromosomal abnormalities using non-invasive prenatal testing under the NIFTY brand, preimplantation chromosomal abnormality and thalassemia carrier gene screening, infectious disease group analysis, and monkeypox virus analysis. It also provides other screening tests, such as cancer-related gene screening to predict the risk of inherited cancer, monitor treatment, select drugs that are appropriate for one's genetics, and provide treatment and disease prevention. In addition, the company offers genetic analysis using whole exome sequencing, a technology that can detect gene abnormalities that cause diseases; individual genetic decoding, which involves detailed genetic sequencing to analyze genetic information and identify aspects such as ethnicity or ancestry, optimal exercise profiles, metabolic capabilities, and the risk of genetic diseases; newborn screening; and health check-ups for various needs. Further, it supports research services in both medical and other fields, offers DNA and RNA sequencing, metabolomics and proteomics services, and medical products comprising genetic sequencers; NIPT, PGT-A, hereditary cancer screening, and precision oncology solutions; real-time PCR that includes beta thalassemia genotyping and human papillomavirus genotyping kits; and cell-free DNA storage tubes. The company serves government sectors such as medical schools and health centers, as well as private sectors such as clinics, hospitals, private medical laboratories, research institutes, and universities. Bangkok Genomics Innovation Public Company Limited was founded in 2017 and is headquartered in Bangkok, Thailand.